Mecapegfilgrastim

DB19147InvestigationalProtein Based Therapies

Mecapegfilgrastim is under investigation in clinical trial NCT05463601 (Mecapegfilgrastim for the Prevention of Dalpiciclib -Induced Neutropenia in Advanced Breast Cancer).

Mechanism: Pharmacologically active on Granulocyte colony-stimulating factor receptor
Curator reviewed
Also known as: Poly(oxy-1,2-ethanediyl), .alpha.-(((2-((3-(3-((3-aminopropyl)thio)-2,5-dioxo-1-pyrrolidinyl)-1-oxopropyl)amino)ethyl)amino)carbonyl)-.omega.-methoxy-, reaction products with granulocyte colony-stimulating factor (methionyl)(human)
Code names: HHPG-19K

Resolves to

Compound

UNIII4QL0KKG3KCAS1570067-55-8

Targets

Q99062CSF3R

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Mecapegfilgrastim, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account